Abstract
Ripretinib, a kinase switch-control inhibitor designed to broadly inhibit KIT and PDGFRA mutations, is indicated in the treatment of adult patients (pts) with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior tyrosine kinase inhibitors (TKIs), including imatinib. We present results of the KIT-altered (mutated or amplified) melanoma cohort in an ongoing phase I trial (NCT02571036). There are no approved TKIs for KIT-altered metastatic melanoma; ESMO and NCCN guidelines recommend specified KIT inhibitors as second-line therapy in certain situations; however, reported objective response rate (ORR) is typically <20% and progression-free survival (PFS) 3–4 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
